MAP1LC3A and chronic myelogenous leukemia, BCR-ABL1 positive: ATG7 and ATG4B, both key enzymes in the LC3 conjugation cascade, have been shown to play a critical role in CML CD34+ cell survival, while their genetic inhibition resulted in increased apoptosis of CML stem and progenitor cells and sensitized them to TKI therapy [76,77].